Mathieu-Panchoa de SÈZe

Mathieu-Panchoa de SÈZe

Auto-generated profile, based on publicly available information

Mathieu-Panchoa de SÈZe

Service de Rééducation Fonctionnelle Neurologique, Centre Hospitalier Universitaire de Bordeaux, Hôpital Pellegrin Tastet-Girard, Bordeaux, France

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1999 in European Urology
Verified
Journal Article
Closed access
PDF file
MSMarianne de SÈZe
Marianne de SÈZe
LWLaurent Wiart
Laurent Wiart
JFJean-Marie FerriÈRe
Jean-Marie FerriÈRe
MSMathieu-Panchoa de SÈZe
Mathieu-Panchoa de SÈZe
PJPierre-Alain Joseph
Pierre-Alain Joseph
MBMichel Barat
Michel Barat
Objectives: Interest in the intravesical instillation of capsaicin is growing among urologists. Its efficacy on detrusor hyperreflexia, hypersensitive bladder disorders and bladder pain has been reported in several studies. However, the lack of common evaluation parameters and the absence of consensus concerning a protocol of instillation hamper the interpretation of results. The purpose of this review is to better delineate the indications and optimum protocol for intravesical use of capsaicin. Methods: Eight open and two placebo-controlled human clinical trials were analyzed. All 200 patients involved had lower urinary tract disorders. Results: Clinical or urodynamic symptoms improved in 84.3% of the patients who received intravesical capsaicin for neurogenic hyperreflexic bladder, a significantly greater efficacy than that of placebo. Capsaicin may also be beneficial in patients who have non-neurogenic disorders. Whether or not the patients has a neurologic deficit, side effects appear during and in the period immediately following instillation. Conclusions: Intravesical capsaicin appears to be indicated in neurogenic hyperreflexic bladder, but is less effective against detrusor instability, hypersensitive bladder disorders or pelvic pain. The best instillation protocol and long-term tolerance remain to be established.